Preclinical pharmacology, antitumor activity and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930

類似資料

• CCT244747 is a novel, potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs
  著者:: Walton, Mike I, 等
  出版事項: (2012)
• The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eμ-MYC driven B-cell lymphoma
  著者:: Walton, Mike I., 等
  出版事項: (2015)
• Discovery of 4-Amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides As Selective, Orally Active Inhibitors of Protein Kinase B (Akt)
  著者:: McHardy, Tatiana, 等
  出版事項: (2010)
• The Aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo
  著者:: Faisal, Amir, 等
  出版事項: (2011)
• CCT241533 is a potent and selective inhibitor of CHK2 which potentiates the cytotoxicity of PARP inhibitors
  著者:: Anderson, Victoria E, 等
  出版事項: (2011)